Form 4: Aclaris Therapeutics' Chief Medical Officer Receives Stock Options and Restricted Stock Units

Jesse Wayne Hall, Chief Medical Officer of Aclaris Therapeutics, was granted stock options and restricted stock units on May 1, 2025, according to a Form 4 filing.

Summary

• Jesse Wayne Hall, the Chief Medical Officer of Aclaris Therapeutics, Inc., received stock options and restricted stock units on May 1, 2025.
• Hall was granted 510,000 employee stock options with an exercise price of $1.38, expiring on April 30, 2035.
• These options vest in four equal installments annually, starting May 1, 2025.
• Hall also received 145,500 restricted stock units, each representing a contingent right to receive one share of common stock.
• These restricted stock units vest in four equal installments annually, starting May 1, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, incentivizing management and aligning interests with shareholders.

Positives

• The grant of stock options and restricted stock units aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of Aclaris Therapeutics' stock.
• If Hall leaves the company before the vesting dates, he may forfeit unvested options and units.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Grants of stock options and restricted stock units are common practices in the pharmaceutical industry to attract, retain, and incentivize key executives.

Comparison to Industry Standards

• Stock option grants to key executives are a standard practice in the biopharmaceutical industry.
• Companies like Amgen, Gilead, and Regeneron routinely use equity-based compensation to align executive incentives with shareholder value.
• The vesting schedules and option terms are generally comparable to industry norms, with vesting periods typically spanning 3-4 years.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Aclaris Therapeutics, Jesse Wayne Hall, Chief Medical Officer, Stock Options, Restricted Stock Units, Form 4, ACRS, Vesting